Combination of docetaxel, trastuzumab and pertuzumab or treatment with trastuzumab-emtansine for metastatic salivary duct carcinoma

Saved in:
Bibliographic Details
Published inOral oncology Vol. 72; pp. 198 - 200
Main Authors van Boxtel, Wim, Boon, Eline, Weijs, Willem L.J., van den Hoogen, Frank J.A., Flucke, Uta E., van Herpen, Carla M.L.
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.09.2017
Subjects
Ado-trastuzumab emtansine
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms
Docetaxel
Head and Neck Neoplasms
Maytansine
Neoplasm metastasis
Pertuzumab
Receptor, ErbB-2
Salivary duct carcinoma
Salivary Ducts
Salivary gland neoplasms
Taxoids
Trastuzumab
Salivary gland neoplasms
Pertuzumab
Docetaxel
Salivary duct carcinoma
Receptor, ErbB-2
Ado-trastuzumab emtansine
Neoplasm metastasis
Head and Neck Neoplasms
Trastuzumab
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ObjectType-Commentary-2
ISSN:1368-8375
1879-0593
DOI:10.1016/j.oraloncology.2017.06.023